spacerspacerspacerspacerspacer
Center for BiosecurityUPMC | University of Pittsburgh Medical Center

Give us feedback | Search | Sitemap | Home

horizontal rulespacer


Areas of Focus

  
Special Topics   
Resources The Center

 

This Website is supported by funding from the Alfred P. Sloan Foundation.
Home > Biosecurity Briefing > Archive > Countermeasure Development
Tools:||Link to this page| Share this page
horizontal rule
spacer

Biosecurity Briefing

Subscribe | About | Current Issue | RSS | Archive

Countermeasure Development Archive

Anthrax | Smallpox | Influenza | General

Anthrax

Bio Briefing - Countermeasures: Anthrax

Biosecurity Briefing articles relating to anthrax countermeasure developments.

  1. NIAID, BARDA Award Anthrax Vaccine Contracts, Ebola/Marburg Contracts (10-06-2008)

    Biosecurity Briefing: NIAID, BARDA awarded contracts to develop a next generation anthrax vaccine, as well as two contracts for development of a multivalent Ebola and Marburg vaccine.
    Tue, 07 Oct 2008 15:55:10 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-niaidbardavaccontracts.html

  2. HHS Takes Preparedness Measures for Anthrax; Requests Antibiotic Kit EUA for Postal Carriers, Liability Protection for Private Sector Businesses (10-06-2008)

    Biosecurity Briefing: HHS announced that the dept. has called for 2 measures to prepare for an anthrax attack--issue kits containing antibiotics for postal workers and liability protections for private sector businesses engaged in some cntr. measures.
    Mon, 06 Oct 2008 21:02:38 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-hhsprepanthrax.html

  3. BARDA, NIAID Award Anthrax Monoclonal Antibody Contract; NIAID Awards Botulinum Antitoxin Contract (09-15-2008)

    Biosecurity Briefing: On September 3, 2008, Emergent BioSolutions, Inc., announced that it had been awarded a $24.3 million contract to develop its anthrax monoclonal antibody AVP-21D9. The contract was awarded jointly by BARDA and NIAID.
    Tue, 16 Sep 2008 14:32:36 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-15-anthraxantibodybotulinumantitox.html

  4. India Imports Anthrax Vaccine, Bangladesh Expands Bird Flu Program (06-13-2008)

    Biosecurity Briefing: The Times of India reported that a company in India has imported 200 doses of Biothrax, the only anthrax vaccine approved by the FDA. Xinhua News Agency reported that neighboring Bangladesh is expanding its bird flu prep programs.
    Fri, 13 Jun 2008 20:45:39 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-06-13-indiaanthrxvacbangladesh.html

  5. FDA Approves Antimicrobial for Pediatric Inhalational Anthrax Exposure (05-16-2008)

    Biosecurity Briefing: Drug Industry Daily news reports the FDA approved Levaquin (levofloxacin) for use in pediatric patients who have been exposed to Bacillus anthracis. This is the first and only pediatric indication for Levaquin.
    Fri, 16 May 2008 19:23:46 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-05-16-fdaapprovantimicrobialpedathrax.html

  6. HHS Requests Proposals for Next Anthrax Vaccine (03-07-2008)

    Biosecurity Briefing: CQ Politics reported that the HHS released a request for proposals (RFP) for development of a new anthrax vaccine. The RFP requires 25 million doses of a vaccine that can be administered in only three doses.
    Mon, 10 Mar 2008 14:57:04 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-03-07-hhsrfpanthraxvac.html

  7. New Study Suggests ABthrax Protects Monkeys, Rabbits Against Inhalational Anthrax (12-21-2007)

    Biosecurity Briefing: The Human Genome Sciences, Inc., (HGSI) announced results from two animal studies of its treatment drug, ABthrax (raxibacumab) that "...demonstrate a survival benefit in two animal species..."
    Fri, 21 Dec 2007 19:29:24 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/content/anthrax/2007-12-21-studyabthraxprotectsmonkeysrabbits.html

  8. HHS Issues Draft RFP for rPA Anthrax Vaccine (11-30-2007)

    Biosecurity Briefing: The Dept of HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) posted a draft request for proposal for Anthrax recombinant Protective Antigen (rPA) vaccine for the Strategic National Stockpile.
    Mon, 03 Dec 2007 17:28:48 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-11-30-hhsissuesdraftrfprpaanthraxvac.html

  9. House Committee Concerned About Timeline for Acquisition of Anthrax Countermeasures (09-14-2007)

    Biosecurity Briefing: The House Committee on Homeland Security expressed disappointment regarding the pace with which the agency has moved toward the development and procurement of a recombinant protective antigen anthrax vaccine.
    Fri, 14 Sep 2007 21:03:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-09-14-housecomtimeanthraxcounter.html

  10. Study Shows New Adjuvant, Nasal Spray Vaccine May Offer Protection against Anthrax (08-24-2007)

    Biosecurity Briefing: According to a study in Infection and Immunity, anthrax vaccine with a new adjuvant administered nasally provided guinea pigs greater protection against lethal doses of anthrax than the standard vaccine administered by injection.
    Fri, 24 Aug 2007 21:03:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-08-24-studyshowsnewadjuvantprotectagainstanthrax.html

  
[return to top]

Smallpox

Bio Briefing - Countermeasures: Smallpox

Biosecurity Briefing articles relating to smallpox countermeasure developments.

  1. NIAID Awards Additional Funding for Smallpox Antiviral; DTRA Awards $8.3 Million for Research into Broad-Spectrum Antibiotics (09-29-2009)

    Biosecurity Briefing: SIGA Tech. received an award from NIAID to accelerate development of its smallpox antiviral drug ST-246. SRI Intl announced DoD�s DTRA awarded contract to facilitate preclinical research in developing broad spectrum antibiotics.
    Mon, 29 Sep 2008 20:48:47 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-29-niaidfundsmallpxantiviral.html

  2. NIAID and BARDA Award Funding to SIGA Technologies for Orthopoxvirus Antiviral (09-08-2008)

    Biosecurity Briefing: SIGA Technologies, Inc., announced that NIAID and HHS BARDA awarded the pharmaceutical company a $55 million contract to fund the development of additional formulations and smallpox-related indications for its antiviral drug ST-246.
    Tue, 09 Sep 2008 15:53:50 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-08-fundssigatechantiviral.html

  3. Acambis Wins USG Contract for Smallpox Vaccine (04-25-2008)

    Biosecurity Briefing: Reuters reported that British vaccine developer Acambis won a $425 million, 10-year contract to supply the U.S. govt with 9 million doses of the ACAM2000 smallpox vac. each year for delivery to the Strategic National Stockpile.
    Fri, 25 Apr 2008 20:51:43 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/smallpox/2008-04-25-acambisusgsmallpoxvac.html

   
[return to top]

Influenza

Bio Briefing - Countermeasures: Influenza

Biosecurity Briefing articles relating to flu countermeasure developments.

  1. Novartis H5N1 Vaccine Produces Rapid Immunity When Primed With H5N3 Vaccine (10-27-2008)

    Biosecurity Briefing: A study published in the October 9, 2008, issue of the New England Journal of Medicine evaluates the Novartis H5N1 influenza vaccine, which employs a prime-boost strategy to induce immunity.
    Mon, 27 Oct 2008 20:55:28 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-10-27-novartish5n1vacwithh5n3vac.html

  2. Countermeasure Research and Development News Updates (09-22-2008)

    Biosecurity Briefing: GSK results of trials for its pre-pandemic H5N1 vaccine Prepandrix. Vaxin, Inc., announced NIH awarded grant for ongoing development of avian flu vac for poultry. XOMA, Ltd., announced establishment of a MOU with Texas A&M System.
    Mon, 22 Sep 2008 16:02:07 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-22-cntrmeasureranddnews.html

  3. Survey Finds H5N1 Knowledge Low in Afghanistan; Novavax Pandemic Vaccine Promising in Clinical Trial (09-08-2008)

    Biosecurity Briefing: CDC survey assessed factors that affect the knowledge regarding H5N1 in Afghanistan. Novavax, Inc. announced positive results from the 2nd stage of human clinical trial of its pandemic flu virus-like particle vac candidate.
    Tue, 09 Sep 2008 15:32:26 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-09-08-h5n1knowledgelownovavaxpanvac.html

  4. WHO Reports Oseltamivir Resistance in Southern Hemisphere (08-25-2008)

    Biosecurity Briefing: On August 15, 2008, the World Health Organization (WHO) issued a report indicating that clinical samples from the 2008 influenza season provide evidence of a high degree of resistance to the antiviral drug oseltamivir (Tamiflu).
    Mon, 25 Aug 2008 16:32:51 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-08-25-whooseltamivirresistsohemisphere.html

  5. BARDA Announces RFP for H5N1 Vaccine (07-28-2008)

    Biosecurity Briefing: Biomedical Advanced Research and Development Authority (BARDA) announced a RFP for an egg-based inactivated monovalent H5N1 vaccine at commercial scale for inclusion in the Strategic National Stockpile.
    Mon, 28 Jul 2008 21:21:24 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-07-28-bardarfph5n1vac.html

  6. H5N1 News: Australia Approves Vaccine; Sanofi to Donate to WHO Stockpile; HHS Contracts to Develop Rapid Diagnostic Tests (06-20-2008)

    Biosecurity Briefing: Australia approves H5N1 vaccine Panvax, developed by CSL Limited; Sanofi to donate to WHO stockpile to help poor countries; HHS contracts to develop low-cost rapid diagnostic tests for influenza.
    Fri, 20 Jun 2008 20:38:02 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-06-20-h5n1newsaustraliasanofihhs.html

  7. Study Shows Positive Clinical Results for Whole Virus H5N1 Vaccine Grown in Cell Culture (06-20-2008)

    Biosecurity Briefing: NEJM published results from a randomized clinical trial of whole virus H5N1 avian flu vac that was produced in cell-culture. Two doses of unadjuvanted vac produced evidence of a positive immune response for 3 clades of H5N1 virus.
    Fri, 20 Jun 2008 20:19:16 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-06-20-positiveresultsh5n1vac.html

  8. Indonesia Reduces H5N1 Case Reporting to Once Every 6 Months, Accuses Baxter of Delaying Vaccine (06-13-2008)

    Biosecurity Briefing: A Reuters article describes Indonesia's new avian influenza reporting policy, which will now require human cases of avian influenza to be reported once every six months rather than immediately upon recognition.
    Fri, 13 Jun 2008 21:00:17 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-06-13-indonesiareducesh5n1reportng.html

  9. WHO Document Guides Strategic Use of H5N1 Vaccine and Vaccine Stockpile (05-23-2008)

    Biosecurity Briefing: On May 16, 2008, the World Health Organization (WHO) released a document that discusses options for human use of H5N1 influenza vaccine as well as options for use of the WHO H5N1 vaccine stockpile.
    Fri, 23 May 2008 19:55:13 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-05-23-whoguideh5n1vacstock.html

  10. EU Grants Marketing License for Pre-Pandemic Flu Vaccine (05-23-2008)

    Biosecurity Briefing: The Associated Press reported that GlaxoSmithKline has been granted a marketing license by the European Commission to begin distributing the first "pre-pandemic" influenza vaccine to hit the European market.
    Fri, 23 May 2008 19:40:34 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-05-23-eulicenseprepanfluvac.html

  11. HHS Spends $192.5 Million on H5N1 Vaccine (05-02-2008)

    Biosecurity Briefing: CIDRAP reported that the HHS purchased $192.5 million worth of clade 2.2 H5N1 vaccine from sanofi pasteur. The purchase will provide 6.4 to 38.5 million doses of the vaccine to the Strategic National Stockpile (SNS).
    Mon, 05 May 2008 16:20:01 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/2008-05-02-hhsspends192mh5n1vaccine.html

  12. H5N1 Vaccine Adjuvant Patch Enters Phase II Trials (04-18-2008)

    Biosecurity Briefing: Reuters reported that Iomai, a small Gaithersburg, MD, biotechnology company, received "U.S. [Department of Health and Human Services] approval..." to begin phase II clinical trials testing "a bird flu skin patch on more people."
    Fri, 18 Apr 2008 19:55:36 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-04-18-h5n1vacadjuvantpatchphase2.html

  13. First Pre-Pandemic Flu Vaccine Recommended for EU-Wide Marketing License (03-07-2008)

    Biosecurity Briefing: The European Medicines Agency, equivalent of U.S. FDA, announced that it recommends "the authorization of...[Europe's] first 'pre-pandemic vaccine' for humans against influenza caused by the H5N1 virus."
    Mon, 10 Mar 2008 16:20:39 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-03-07-1stprepanfluvaceulicense.html

  14. Flu Season Marked by Vaccine Mismatch, Antiviral Resistance in Europe (02-15-2008)

    Biosecurity Briefing: CDC reports seasonal flu more severe than last 2 years and a mismatch between this year's vac and two of predominant strains of flu. Europe reports unexpected emergence of H1N1 virus with a decreased sensitivity to oseltamivir.
    Tue, 19 Feb 2008 15:31:18 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-02-15-fluvacmismatchresisteurope.html

  15. New Under-the-Tongue Influenza Vaccination Method Studied (02-01-2008)

    Biosecurity Briefing: On January 29, 2008, the International Vaccine Institute (IVI) reported the results of a study that examines a new way of delivering influenza vaccines: sublingually, or under the tongue.
    Fri, 01 Feb 2008 20:40:49 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-02-01-newundertonguefluvacstudy.html

  16. Tamiflu Resistance Found Throughout Europe (02-01-2008)

    Biosecurity Briefing: The European Centre for Disease Prevention and Control reported that "some of the A (H1N1) viruses in circulation this winter are resistant to the antiviral drug oseltamivir (also know by the brand name Tamiflu)."
    Fri, 01 Feb 2008 20:39:52 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/international_biosecurity/2008-02-01-tamifluresistancefound.html

  17. Gates Foundation Awards $39 Million to Develop Flu Vaccines for Resource Poor Countries (01-18-2008)

    Biosecurity Briefing: PATH, an international, non-profit organization, announced a $39 million award from the Bill & Melinda Gates foundation to launch the rapid development of flu vaccines and "innovative vaccine technologies" for developing nations.
    Tue, 22 Jan 2008 13:35:13 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-01-18-gatesawardsmillionsfluvac.html

  18. Influenza Vaccine Trials Report Positive Results; Diagnostic Test Approved by FDA (01-11-2008)

    Biosecurity Briefing: BBAcambis has reported positive results from phase I clinical trials of its new flu vaccine. The FDA announced that "a test that simultaneously detects and identifies 12 specific respiratory viruses" has been cleared for marketing.
    Fri, 11 Jan 2008 19:57:39 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/2008/2008-01-11-fluvactrials.html

  19. FDA Panel Votes for Stronger Warnings on Flu Drugs (11-30-2007)

    Biosecurity Briefing: CIDRAP at the Univ. of Minnesota reported that the FDA's Pediatric Advisory Committee voted to recommend stronger language on warning labels of two antiviral flu medications, oseltamivir (brand name Tamiflu) and zanamivir.
    Mon, 03 Dec 2007 17:51:12 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/avian_pandemic_flu/content/2007/2007-11-30-fdavotesstrongerwarnfludrugs.html

  20. HHS Announces CBRN Advisory Board and Pandemic Vaccine Contracts (06-22-2007)

    Biosecurity Briefing: HHS Secretary Mike Leavitt announced that the agency has established a public health advisory board to provide guidance on chemical, biological, radiological and nuclear (CBRN) threats. He also announced contracts for flu vaccine.
    Fri, 22 Jun 2007 20:36:01 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/content/2007-06-22-hhscbrnadvisorybrdvaxcontracts.html

  
[return to top]

General

Bio Briefing - Countermeasures: General

Biosecurity Briefing articles relating to general countermeasure developments.

  1. NIAID, BARDA Award Anthrax Vaccine Contracts, Ebola/Marburg Contracts (10-06-2008)

    Biosecurity Briefing: NIAID, BARDA awarded contracts to develop a next generation anthrax vaccine, as well as two contracts for development of a multivalent Ebola and Marburg vaccine.
    Tue, 07 Oct 2008 15:55:10 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-10-06-niaidbardavaccontracts.html

  2. NIAID Awards Additional Funding for Smallpox Antiviral; DTRA Awards $8.3 Million for Research into Broad-Spectrum Antibiotics (09-29-2009)

    Biosecurity Briefing: SIGA Tech. received an award from NIAID to accelerate development of its smallpox antiviral drug ST-246. SRI Intl announced DoD�s DTRA awarded contract to facilitate preclinical research in developing broad spectrum antibiotics.
    Mon, 29 Sep 2008 20:48:47 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-09-29-niaidfundsmallpxantiviral.html

  3. DTRA Awards Contract to Study Potential of Cethromycin as Broad-Spectrum Antibiotic (08-18-2008)

    Biosecurity Briefing: Advanced Life Sciences announced the award of a contract from the U.S. Dept of Defense Defense Threat Reduction Agency for advanced development of the antibiotic cethromycin as a potential broad-spectrum medical countermeasure.
    Mon, 18 Aug 2008 14:38:59 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-08-18-dtracontractcethromycin.html

  4. Emergent BioSolutions Wins NIAID Grants, Sanofi to Acquire Acambis (08-04-2008)

    Biosecurity Briefing: Emergent BioSolutions, Inc., announced it has been awarded two grants from NIAID for the development of botulism and next-generation anthrax vaccine candidates. AP reported that sanofi-aventis will acquire vaccine-maker Acambis PLC.
    Mon, 04 Aug 2008 16:15:47 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/other/2008-08-04-emergentniaidsanofiacambis.html

  5. FDA Changes Process for Product Licensure Notification (07-11-2008)

    Biosecurity Briefing: The FDA issued a news release announcing a change in the format of letters that are sent to pharmaceutical companies to inform them of the FDA's decision regarding licensure of pharmaceutical products.
    Mon, 14 Jul 2008 14:21:02 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/2008-07-11-fdaproductlicensenotice.html

  6. Annual Report on Project BioShield Released to Congress (07-11-2008)

    Biosecurity Briefing: HHS announced that the Annual Report to Congress on Project BioShield had been released. This Congressionally mandated report covers progress for the period from August 2006 through July 2007.
    Mon, 14 Jul 2008 13:38:25 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-07-11-annualrptbioshield.html

  7. Cangene Delivers Botulism Antitoxin to SNS; DynPort, DoD Developing Plague Vaccine (06-13-2008)

    Biosecurity Briefing: CNW reported that Canadian pharmaceutical company Cangene made a large delivery of botulism antitoxin (BAT) to the U.S. government, intended for integration into the U.S. Strategic National Stockpile (SNS).
    Fri, 13 Jun 2008 21:05:46 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/2008/2008-06-13-cangenebotulismantitox.html

  8. HHS Announces Director for Biomedical Advanced Research Development Authority (BARDA) (04-18-2008)

    Biosecurity Briefing: On April 14, 2008, the U.S. Department of Health and Human Services (HHS) issued a press release naming Robin Robinson, Ph.D. as the first director of the Biomedical Advanced Research Development Authority (BARDA).
    Fri, 18 Apr 2008 19:45:56 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/2008-04-18-hhsannouncedirectorbarda.html

  9. Ebola Virus Made Safe to Work With in Laboratories (01-25-2008)

    Biosecurity Briefing: The Proceedings of the National Academy of Sciences (PNAS) published a study describing the generation of a new research strain of Ebola virus which would be "safe" to handle "outside of a biosafety level-4 facility."
    Mon, 28 Jan 2008 14:56:30 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/agents_diseases/vhf/2008-01-25-ebolasafelaboratories.html

  10. National Biodefense Science Board Membership Announced, First Meeting Held (12-21-2007)

    Biosecurity Briefing: HHS Secretary Michael Leavitt officially announced the 13 voting members of the National Biodefense Science Board (NBSB). It met for the first time from December 17-18 in Washington, DC.
    Fri, 21 Dec 2007 19:16:48 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/content/2007-12-21-natlbiodefensescienceboard.html

  11. Committee Reports that FDA Has Insufficient Personnel, Resources to Meet Mission (12-07-2007)

    Biosecurity Briefing: A recent report issued by the FDA Science Board's Subcommittee on Science and Technology has concluded that FDA can no longer fulfill its mission without substantial and sustained additional appropriations.
    Fri, 07 Dec 2007 14:01:00 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/govt_response/content/2007-12-07-comrprtsfdainsufficientresources.html

  12. Lower Dose of Vaccine Administered to Broader Population May Reduce Total Number Infected in a Pandemic (06-29-2007)

    Biosecurity Briefing: A paper published PLoS Medicine suggests that infection rates during a flu pandemic could be reduced if more people were vaccinated with lower doses of vaccine rather than if a lesser number of people are vaccinated with full doses.
    Tue, 03 Jul 2007 12:50:23 GMThttp://www.upmc-biosecurity.org/website/biosecurity_briefing/archive/countrmeasr_dev/content/2007/2007-06-29-lowerdoseofvaccine.html

  
[return to top]

  

© 2008 University of Pittsburgh Medical Center. All rights reserved. | About this website